| scholarly article | Q13442814 |
| P2093 | author name string | Yi-Long Wu | |
| Lunxi Peng | |||
| P2860 | cites work | Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer | Q24633070 |
| Crizotinib resistance: implications for therapeutic strategies | Q26738381 | ||
| Radiotherapy combination opportunities leveraging immunity for the next oncology practice | Q26738443 | ||
| Combining radiotherapy and cancer immunotherapy: a paradigm shift | Q27021428 | ||
| EGFR mutation and resistance of non-small-cell lung cancer to gefitinib | Q27824829 | ||
| Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers | Q27851710 | ||
| Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers | Q27853176 | ||
| PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. | Q27853379 | ||
| Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib | Q27861059 | ||
| Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents | Q28087754 | ||
| Comprehensive molecular profiling of lung adenocarcinoma | Q28244995 | ||
| Cancer statistics, 2016 | Q29547383 | ||
| Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients | Q29617771 | ||
| Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer | Q29620301 | ||
| Pembrolizumab for the treatment of non-small-cell lung cancer | Q29620851 | ||
| Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 | ||
| Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 | ||
| Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. | Q30275719 | ||
| Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial | Q30277192 | ||
| Update on the role of ipilimumab in melanoma and first data on new combination therapies | Q30585096 | ||
| Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer | Q33738921 | ||
| Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China | Q33876861 | ||
| Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study | Q33880042 | ||
| A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER) | Q34041754 | ||
| Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer | Q35463514 | ||
| Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer. | Q35817265 | ||
| Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study | Q35849985 | ||
| Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer | Q36352827 | ||
| Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). | Q36400381 | ||
| Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study | Q36404761 | ||
| Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors | Q36879415 | ||
| The global burden of liver disease: the major impact of China | Q36901892 | ||
| Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma | Q36980597 | ||
| Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). | Q37126929 | ||
| Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors | Q37609786 | ||
| PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis | Q37685959 | ||
| Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance | Q38124438 | ||
| Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? | Q38447992 | ||
| Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? | Q38541770 | ||
| Potential biomarker for checkpoint blockade immunotherapy and treatment strategy. | Q38700735 | ||
| Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. | Q38760078 | ||
| Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy | Q38827684 | ||
| EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB. | Q38872276 | ||
| Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial | Q38906747 | ||
| Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation | Q38912283 | ||
| The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4. | Q38919859 | ||
| PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer? | Q39033713 | ||
| Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. | Q39048866 | ||
| Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors | Q39089944 | ||
| Elements of cancer immunity and the cancer-immune set point | Q39094764 | ||
| Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. | Q39118471 | ||
| Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. | Q39354156 | ||
| Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial | Q39396355 | ||
| Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer | Q39646977 | ||
| Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial | Q40163779 | ||
| Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial | Q40231174 | ||
| Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. | Q40408396 | ||
| Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. | Q40534742 | ||
| Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer | Q41019077 | ||
| EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. | Q41112103 | ||
| Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer | Q41302377 | ||
| Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer | Q41508440 | ||
| PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause? | Q42644265 | ||
| Radiation and immunotherapy: a synergistic combination. | Q42724344 | ||
| Treating KRAS-mutant NSCLC: latest evidence and clinical consequences | Q42820759 | ||
| Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck | Q43164702 | ||
| Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate | Q43715235 | ||
| Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity | Q46066476 | ||
| Phase I/II study of ipilimumab for patients with metastatic melanoma | Q46087025 | ||
| P2.39: Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab: Track: Immunotherapy | Q46888796 | ||
| EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer | Q47214499 | ||
| Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis | Q47262054 | ||
| Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study | Q47564905 | ||
| Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer | Q47834638 | ||
| Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. | Q47920560 | ||
| Nivolumab versus docetaxel in previously treated advanced non-small cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases | Q50161502 | ||
| Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. | Q50876217 | ||
| 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial | Q51521616 | ||
| Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. | Q52586557 | ||
| Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer | Q52587406 | ||
| Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study | Q52640577 | ||
| 57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC. | Q52868409 | ||
| Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer | Q54339119 | ||
| Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer. | Q54620120 | ||
| Update on immune checkpoint inhibitors in lung cancer | Q56897146 | ||
| Non-small cell lung cancer | Q59565902 | ||
| P433 | issue | Suppl 13 | |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | S1482-S1493 | |
| P577 | publication date | 2018-05-01 | |
| P1433 | published in | Journal of thoracic disease | Q26841814 |
| P1476 | title | Immunotherapy in the Asiatic population: any differences from Caucasian population? | |
| P478 | volume | 10 |
| Q99582721 | A meta-analysis on immune checkpoint inhibitor efficacy for advanced non-small cell lung cancer between East Asians versus non-East Asians |
| Q97537530 | Genomic assessment distinguishes intrapulmonary metastases from synchronous primary lung cancers |
| Q89622208 | KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit |
| Q91649938 | Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis |
Search more.